Eli Lilly’s Orfoscerinib: Jefferies Raises Price Target

Investment banking firm Jefferies raises Eli Lilly's price target based on optimism over orfoscerinib, indicating strong confidence in its potential. This drug represents a significant part of the company's pipeline and has the potential to greatly impact its future growth and market position. With strong financial metrics and commitment to shareholder returns, Eli Lilly is an attractive option for investors.